Menu
Search
|

Menu

Close
X

BioLine RX Ltd BLRX.OQ (NASDAQ Stock Exchange Capital Market)

1.01 USD
+0.01 (+1.00%)
As of 2:29 AM IST
chart
Previous Close 1.00
Open 1.03
Volume 8,672
3m Avg Volume 71,352
Today’s High 1.03
Today’s Low 1.01
52 Week High 1.34
52 Week Low 0.80
Shares Outstanding (mil) --
Market Capitalization (mil) --
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.75 Mean rating from 4 analysts

KEY STATS

Revenue
No Data Available
FY
-
FY
-
FY
-
FY
-
EPS
No Data Available
FY
-
FY
-
FY
-
FY
-

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.90
Price to Sales (TTM)
vs sector
--
5.77
Price to Book (MRQ)
vs sector
--
5.41
Price to Cash Flow (TTM)
vs sector
--
23.42
Total Debt to Equity (MRQ)
vs sector
--
16.52
LT Debt to Equity (MRQ)
vs sector
--
12.22
Return on Investment (TTM)
vs sector
--
14.43
Return on Equity (TTM)
vs sector
--
16.13

EXECUTIVE LEADERSHIP

Aharon Schwartz
Chairman of the Board, Since 2003
Salary: --
Bonus: --
Philip Serlin
Chief Executive Officer, Since 2016
Salary: --
Bonus: --
Mali Zeevi
Chief Financial Officer, Since 2016
Salary: --
Bonus: --
Merril Gersten
Chief Scientific Officer, Since 2016
Salary: --
Bonus: --
Moshe Phillip
Vice President of Medical Affairs and Senior Clinical Advisor, Since 2004
Salary: 736,000.00₪
Bonus: 110,000.00₪

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

Modi'in Technology Park
2 HaMa'ayan Street
MODIIN     7177871

Phone: +9728.6429100

BioLine RX Ltd is an Israel-based company engaged in the development of therapeutics, from preclinical-stage development to advanced clinical trials, for a range of medical needs. Its clinical therapeutic candidates under development consist of BL-1020 that is in Phase II/III clinical trials to improve cognitive function in schizophrenia patients; BL-1040, which is under pivotal CE-Mark registration trial for the prevention of cardiac remodeling following an acute myocardial infarction; BL-5010, which has completed Phase I/II clinical trials for non-surgical removal of skin lesions; BL-1021 that has completed Phase Ia clinical trial for the treatment of neuropathic pain or pain that results from damage to nerve fibers, and BL-7040, a synthetic oligonucleotide, which is in Phase II clinical trial for the treatment of inflammatory bowel disease. The Company also has 11 pre-clinical stage development products for various indications.

SPONSORED STORIES